IgE-dependent sensitization in patients with COPD
Andrzej Bożek 1  
More details
Hide details
Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, Katowice, Poland
Clinical Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland
Introduction and objective:
The aim of the study was to evaluate the differences between asthma and COPD on the basis of the prevalence and profile of IgE-dependent sensitization to inhaled allergens, and the blood serum levels of select Th1/Th2 cytokines.

Material and methods:
103 patients with COPD (114 patients with asthma and 121 controls) were included in the study. A skin prick test with common inhaled allergens was performed, and serum levels of IgE were measured in all subjects. Lymphocyte profiles were measured via the whole-blood method using fresh 10-ml blood samples treated with EDTA. The following surface antigens were measured: CD3, CD29, CD16, CD56, CD4, CD8, and HLA-DR. The Th1/Th2 profile in blood serum was determined using Th1/Th2 cytokine kits.

IgE-dependent sensitization to environmental allergens was found in 34 (33.3%) patients with COPD, 46 (40%) patients with asthma and in 14 (11.5%) volunteers. The odds ratio of sensitization in patients with COPD reached 0.89 (95% CI: 0.57–1.08) and it was more frequent than in the control population with an odds ratio of 0.71 (95% CI: 0.64–0.88). The serum concentration of IL-2 was significantly higher in patients with COPD and asthma than in controls. In the subgroup of patients with non-allergic asthma, similar serum concentrations were observed for all analyzed cytokines, except for IFN-gamma, which was lower in patients with COPD.

Both the prevalence and profile of IgE-dependent sensitization to inhaled allergens did not differ between asthma and COPD. Both Th2 and Th1 played a role in the immunopathology of asthma and COPD.

COPD – Chronic Obstructive Pulmonary Disease; FEV1 – forced expiratory volume in one second; FVC – forced expiratory volume; GINA – Global Initiative for Asthma; GOLD – Global Initiative for Chronic Obstructive Lung Disease; MMRC – Modified Medical Research Council; Th1 – lymphocyte helper 1; Th2 – lymphocyte helper 2

Andrzej Bożek   
Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, Katowice, Skłodowskiej 10, 41-800 Zabrze, Poland
1. Barnes PJ. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol. 2015; 136: 531–45.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Updated 2015. http//: (accessed 20.01.16).
3. Global Initiative for Asthma GINA. http//: (accessed 22.03.15).
4. Mathur SK, Viswanathan RK. Relevance of allergy in adult asthma. Curr Allergy Asthma Rep. 2014; 14: 437.
5. Neves MC, Neves YC, Mendes CM, Bastos MN, Camelier AA, Queiroz CF, Mendoza BF, Lemos AC, D’Oliveira Junior A. Evaluation of atopy in patients with COPD. J Bras Pneumol. 2013; 39: 296–305.
6. Fattahi F, ten Hacken NH, Löfdahl CG, Hylkema MN, Timens W, Postma DS,Vonk JM. Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study. Respir Res. 2013; 28 (14):10.
7. Braman SS. The chronic obstructive pulmonary disease-asthma overlap syndrome. Allergy Asthma Proc. 2015; 36: 11–8.
8. Heinzerling LM, Burbach GJ, Edenharter G, Bachert C, Bindslev-Jensen C, Bonini S, et al. GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy. 2009; 64: 1498–1506.
9. Hizawa N. Clinical approaches towards asthma and chronic obstructive pulmonary disease based on the heterogeneity of disease pathogenesis. Clin Exp Allergy. 2016; 46: 678–87.
10. Ichinose M. Differences of inflammatory mechanisms in asthma and COPD. Allergol Int. 2009; 58: 307–13.
11. Li BW, Hendriks RW. Group 2 innate lymphoid cells in lung inflammation. Immunology. 2013; 140: 281–287.
12. Tsai JJ, Liao EC, Hsu JY, Lee WJ, Lai YK. The differences of eosinophil-and neutrophil-related inflammation in elderly allergic and non-allergic chronic obstructive pulmonary disease. J Asthma. 2010; 47: 1040–4.
13. Ogershok PR, Warner DJ, Hogan MB, Wilson NW. Prevalence of pollen sensitization in younger children who have asthma. Allergy Asthma Proc. 2007; 28: 654–658.
14. Pawankar R, Canonica GW, Holgate ST, Lockey RF. Allergic diseases and asthma: a major global health concern. Curr Opin Allergy Clin Immunol. 2012; 12: 39–41.
15. Simpson CR, Anderson WJ, Helms PJ, Taylor MW, Watson L, Prescott GJ, Godden DJ, Barker RN. Coincidence of immune-mediated diseases driven by Th1 and Th2 subsets suggests a common aetiology. A population-based study using computerized general practice data. Clin Exp Allergy. 2002; 32: 37–42.
16. Holt PG, Sly PD. Non-atopic intrinsic asthma and the ‘family tree’ of chronic respiratory disease syndromes. Clin Exp Allergy. 2009; 39: 807–11.
17. Ngoc PL, Gold DR, Tzianabos AO, Weiss ST, Celedón JC. Cytokines, allergy, and asthma. Curr Opin Allergy Clin Immunol. 2005; 5; 161–166.
18. Shirai T, Inui N, Suda T, Chida K. Correlation between peripheral blood T-cell profiles and airway inflammation in atopic asthma. J Allergy Clin Immunol. 2006; 118: 622–6.
19. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007; 96: 41–101.
20. Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011; 23: 598–604.
21. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010; 27:153–65.
22. Perkins PC, Wills-Karp M, Finkelman FD. IL-4 induces IL-13-independent allergic airway inflammation. J Allergy Clin Immunol. 2006; 118: 410–9.